HER2 Support Group Forums - View Single Post

agness · 09-11-2015, 11:29 AM

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
http://www.breast-cancer-research.co...df/bcr2944.pdf
[2011, Breast Cancer Research] -- this predates Herceptin and Perjeta but the protein links is very interesting and might help with tissue genetic profiling.

" Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and
infrequently ER and PgR."

Breast cancer molecular subtype: HER2+/HR-
No. of patients: 36
No. of metastatic sites: 48
Bone: 14 (29.2)
Liver: 13 (27.1)
Lung: 11 (22.9)
Non-regional lymph nodes: 4 (8.3)
Skin: 4 (8.3)
Pleura: 0 (0.0)
Brain: 1 (2.1)
Other 1 (2.1

09-11-2015, 11:29 AM	#7
agness Senior Member Join Date: Aug 2014 Location: Seattle, WA Posts: 285	Re: Compiling Data on HER2 Brain Mets Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study http://www.breast-cancer-research.co...df/bcr2944.pdf [2011, Breast Cancer Research] -- this predates Herceptin and Perjeta but the protein links is very interesting and might help with tissue genetic profiling. " Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR." Breast cancer molecular subtype: HER2+/HR- No. of patients: 36 No. of metastatic sites: 48 Bone: 14 (29.2) Liver: 13 (27.1) Lung: 11 (22.9) Non-regional lymph nodes: 4 (8.3) Skin: 4 (8.3) Pleura: 0 (0.0) Brain: 1 (2.1) Other 1 (2.1 __________________ Dx 2/14 3b HER2+/HR- left breast, left axilla, internal mammary node (behind breast bone). Neoadjuvant TCHP 3/14-7/2. PCR 8/14 LX and SND. 10/21-12/9 Proton therapy to chest wall. Dx 7/20/15 cerebellar met 3.5x5cm HER2+/HR-/GATA3+ 7/23/15 Craniotomy. 7/29/15 bone scan clear. 8/3/15 PET clean scan. LINAC SRS (5 fractions) Sept 2015. 9/17/15 CSF NED, 9/24/15 CSF NED, 11/2/15 CSF NED. 10/27/15 atypical uptake in right cerebellum - inflammation? 12/1/15 Leptomeningeal dx. Starting IT Herceptin. 1/16 - 16 fractions of tomotherapy to cerebellum, break of IT Herceptin during rads, resume at 100 mg weekly 3/2016 - stable scan 5/2016 stable scan 7/2016 pseudoprogression? 9/2016 more LM, start new chemo protocol and IV therapy treatment with HBOT 11/2016 Cyberknife to temporal lobe, HBOT just prior 12/2016 - lesions starting to show shrinkage 8/2017 - Stable since Dec 2016. Temporal lobe lesion gone. Using TCM, naturopathic oncology, physical therapy, chiro, massage, medical qigong, and energetic healing modalities in tandem. Stops at nothing. Mother of 2 boys - ages 7 and 10 (8/2017) and a lovely partner with lots to live for.